[Activity of B663 in lepromatous leprosy. Therapeutic trial].
D000293:Adolescent; D000328:Adult; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000009:adverse effects; D001284:Atrophy / Q000139:chemically induced; D004345:Drug Industry; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007918:Leprosy / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000209:etiology; D010619:Phenazines / Q000009:adverse effects / Q000627:therapeutic use*; D010859:Pigmentation Disorders / Q000139:chemically induced; D011379:Prognosis; D012871:Skin Diseases / Q000139:chemically induced
D000890:Anti-Infective Agents; D010619:Phenazines
Activités du B663 dans la lèpre lépreomateuse. Essai thérapeutque.